Clinical trials: Breast Cancer, Metastatic
Metastatic Triple-Negative Breast Cancer
Olinvacimab With Pembrolizumab in Patients With mTNBC
The objective is to evaluate the efficacy and safety of Olinvacimab in combination with Pembrolizumab in patients with mTNBC.
- Trial name
- NCT04986852
- Testing
- Olinvacimab
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- PharmAbcine
Breast Cancer
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options.
- Trial name
- NCT06665178
- Testing
- Sacituzumab Govitecan
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic breast cancer patients who recieved…
- Trial name
- NCT02030678
- Testing
- irinotecan
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Breast Cancer
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes
The purpose of this study is to determine whether cabazitaxel is effective in the treatment of metastatic breast cancer.
- Trial name
- NCT01693549
- Testing
- Cabazitaxel
- Where
- 17 sites in Greece
- Volunteers
- 84 people
- Sponsor
- Hellenic Cooperative Oncology Group
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
This phase II clinical trial studies how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with advanced, metastatic, or recurrent triple negative invasive breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT01151449
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Lymph Node Metastasis
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes.
- Trial name
- NCT07025785
- Testing
- Circulating tumor DNA
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Triple Negative Breast Cancer, Safety Issues
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
Evaluating efficacy and safety of bevacizumab when combined with chemotherapy (carboplatin and Paclitaxel ) in treatment of patient with metastatic triple negative breast cancer
- Conditions
- Metastatic Triple Negative Breast Cancer, Safety Issues, Efficacy
- Trial name
- NCT03577743
- Testing
- Bevacizumab
- Where
- Egypt
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Assiut University
Male Breast Cancer
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).
- Trial name
- MALE (NCT01638247)
- Testing
- Tamoxifen, Tamoxifen and GnRH analogue, Exemestane and GnRH analogue
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- GBG Forschungs GmbH
Advanced Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8
Living Well With Advanced Breast Cancer
This study evaluates the use of supportive care in patients with advanced breast cancer to better understand what has helped them, what has been hard, and what kind of help they still need.
- Conditions
- Advanced Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
- Trial name
- NCT07227038
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Neoplasms
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line…
- Trial name
- PERUSE (NCT01572038)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 299 sites in Algeria, Argentina and 37 more
- Volunteers
- 1,436 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of FS-1502 versus T-DM1 in HER2-positive, unresectable locally advanced or metastatic breast cancer subjects previously treated with…
- Trial name
- NCT05755048
- Testing
- Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
- Where
- 56 sites in China
- Volunteers
- 314 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Cancer, Cancer Metastatic
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors.
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer
- Trial name
- NCT05131815
- Testing
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Breast Cancer
Reliability and Reproducibility of Bandaging in Breast Cancer
Functional Compressive Bandage (ECF) is a widely used therapeutic resource in the control of lymphedema resulting from the treatment of breast cancer, however, the effects inherent to the technique depend on the quality of the…
- Trial name
- NCT04076033
- Testing
- functional compressive bandage
- Where
- Brazil
- Volunteers
- 23 people
- Sponsor
- Elaine Caldeira de Oliveira Guirro
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
This study plans to enroll 30 patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are scheduled to receive at least two cycles of a regimen containing an immune checkpoint inhibitor (ICI).
- Conditions
- Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT
- Trial name
- NCT07705438
- Testing
- [68Ga]Ga-DOTA-GSI PET/CT (Granzyme B PET/CT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Prostatic Neoplasms, Breast Cancer
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
The primary objective is: To determine the efficacy of modafinil in the reduction of fatigue in patients with metastatic breast or prostate cancer undergoing docetaxel-based chemotherapy The secondary objectives are: To determine…
- Trial name
- NCT00917748
- Testing
- DOCETAXEL(XRP6976) + MODAFINIL, Modafinil
- Where
- Australia
- Volunteers
- 84 people
- Sponsor
- Sanofi
Breast Cancer
Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases
This is an open labelled study. It was designed to evaluate the safety of multiple-dosing of TK006 in patients with breast cancer-related bone metastases.
- Trial name
- NCT03487055
- Testing
- TK006
- Volunteers
- 30 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Breast Cancer
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00265733
- Testing
- capecitabine, paclitaxel poliglumex
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
OligoProgressive Metastatic Disease
Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)
The Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progressive disease at 1-3…
- Trial name
- NCT06925984
- Testing
- SBRT
- Where
- 5 sites in Belgium
- Volunteers
- 48 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Lobular Breast Carcinoma
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC.
- Conditions
- Breast Cancer, Lobular Breast Carcinoma, Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT06557148
- Testing
- 18F-Fluoroestradiol PET/CT
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER2 Negative Metastatic Breast Cancer
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers…
- Trial name
- NCT01948843
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Polaris Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.